CRISPR Therapeutics AG
CRSP57.840USD
+1.580+2.81%
收盤 09/15, 16:00（美東）報價延遲15分鐘
5.11B總市值
虧損本益比TTM
關於 CRISPR Therapeutics AG 公司
CRISPR Therapeutics AG 是一家總部位於瑞士的基因編輯公司，專注於開發基於 CRISPR/Cas9 的療法。CRISPR/Cas9 代表成簇的規律間隔短迴文重複序列 (CRISPR)/CRISPR 相關蛋白 9 (Cas9)，是一種基因編輯技術，即精確改變基因組 DNA 特定序列的過程。該公司旨在應用這項技術來破壞、刪除、糾正和插入基因，以治療基因定義的疾病並設計先進的細胞療法。該公司已獲得涵蓋 CRISPR/Cas9 和相關技術的知識產權 (IP) 的權利，並且還參與了自己的知識產權研究和其他許可工作。公司的產品開發和合作戰略旨在充分利用 CRISPR/Cas9 平臺的潛力，同時最大限度地提高成功開發其候選產品的可能性。
公司簡介
公司代碼CRSP
公司名稱CRISPR Therapeutics AG
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
員工數量393
證券類型Ordinary Share
年結日Oct 19
公司地址Baarerstrasse 14
城市ZUG
上市交易所NASDAQ Global Market Consolidated
國家Switzerland
郵編6300
電話41415613279
網址https://crisprtx.com/
公司代碼CRSP
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
292.63K
+4.25%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
292.63K
+4.25%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Global Advisors (US)
3.60%
其他
69.05%
持股股東
持股股東
佔比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Global Advisors (US)
3.60%
其他
69.05%
股東類型
持股股東
佔比
Investment Advisor
46.51%
Investment Advisor/Hedge Fund
21.68%
Hedge Fund
3.78%
Venture Capital
3.45%
Research Firm
3.18%
Individual Investor
1.64%
Bank and Trust
1.57%
Pension Fund
0.45%
Sovereign Wealth Fund
0.45%
其他
17.31%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
949
75.06M
82.87%
+271.52K
2025Q1
952
68.11M
78.87%
-5.61M
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
ARK Investment Management LLC
10.17M
11.77%
+1.19M
+13.29%
Mar 31, 2025
Capital International Investors
6.07M
7.03%
-2.67M
-30.54%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.41M
2.8%
-100.08K
-3.98%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.80M
4.4%
-13.61K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
2.41M
2.79%
-80.26K
-3.22%
Mar 31, 2025
Two Sigma Investments, LP
1.99M
2.3%
+1.60M
+407.93%
Mar 31, 2025
Orbis Investment Management Ltd.
1.56M
1.81%
+86.81K
+5.88%
Mar 31, 2025
UBS Financial Services, Inc.
1.73M
2%
-94.39K
-5.18%
Mar 31, 2025
Amova Asset Management Co., Ltd.
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
Amova Asset Management Americas, Inc
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
9.19%
Global X Genomics & Biotechnology ETF
5.61%
ARK Innovation ETF
4.11%
AXS Green Alpha ETF
3.95%
WisdomTree BioRevolution Fund
3.07%
SPDR S&P Biotech ETF
1.51%
Amplify Small-Mid Cap Equity ETF
1.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
iShares Exponential Technologies ETF
0.52%
iShares Biotechnology ETF
0.41%
查看更多
ARK Genomic Revolution ETF
佔比9.19%
Global X Genomics & Biotechnology ETF
佔比5.61%
ARK Innovation ETF
佔比4.11%
AXS Green Alpha ETF
佔比3.95%
WisdomTree BioRevolution Fund
佔比3.07%
SPDR S&P Biotech ETF
佔比1.51%
Amplify Small-Mid Cap Equity ETF
佔比1.07%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.86%
iShares Exponential Technologies ETF
佔比0.52%
iShares Biotechnology ETF
佔比0.41%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
